Open AccessThis article is
- freely available
The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML)
Department of Medicine and Oncology, Segal Cancer Centre, Jewish General Hospital, Montreal, QC, H3T 1E2, Canada
Department of Pathology and Cell Biology, Institute of Research in Immunology and Cancer (IRIC), Université de Montréal, Pavillion Marcelle-Coutu, Chemin Polytechnique, Montreal, QC, H3T 1J4, Canada
* Authors to whom correspondence should be addressed.
Received: 22 August 2012; in revised form: 29 September 2012 / Accepted: 17 October 2012 / Published: 2 November 2012
(This article belongs to the Special Issue Leukemia
Abstract: Acute myeloid leukemia (AML) is nearly always a fatal malignancy. For the past 40 years, the standard of care remains a combination of cytarabine and an anthracycline known as 7 + 3. This treatment regimen is troubled by both low survival rates (10% at 5 years) and deaths due to toxicity. Substantial new laboratory findings over the past decade have identified many cellular pathways that contribute to leukemogenesis. These studies have led to the development of novel agents designed to target these pathways. Here we discuss the molecular underpinnings and clinical benefits of these novel treatment strategies. Most importantly these studies demonstrate that clinical response is best achieved by stratifying each patient based on a detailed understanding of their molecular abnormalities.
Keywords: acute myeloid leukemia; targeted therapies; early phase trials
Citations to this Article
Cite This Article
MDPI and ACS Style
Assouline, S.; Cocolakis, E.; Borden, K.L.B. The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML). Cancers 2012, 4, 1161-1179.
Assouline S, Cocolakis E, Borden KLB. The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML). Cancers. 2012; 4(4):1161-1179.
Assouline, Sarit; Cocolakis, Eftihia; Borden, Katherine L.B. 2012. "The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML)." Cancers 4, no. 4: 1161-1179.